BMY

Surveying 3Q Performance from Big Pharma: Bristol-Myers, Eli Lilly, and AbbVie

by

Bristol-Myers On Wednesday, Bristol-Myers (BMY) showcased the strength of its key marketed products in its third-quarter report. The firm experienced a 9% increase in net sales and a 12% jump in non-GAAP diluted earnings per share. Bristol-Myers also confirmed its 2013 non-GAAP earnings per share range of $1.70 to $1.78 per share. Looking at its current marketed portfolio, Abilify, its largest revenue generator, faced a 16% decline, though this was offset by strength in Yervoy, which grew 33%, Orencia, which grew 22%, and Sprycel, which grew 20%. Yervoy doesn’t lose exclusivity in key markets until after 2020 (2023 in the US), Orencia loses exclusivity in Japan, the EU, and the US between years 2017 and 2019, and Sprycel doesn’t lose … Read more

ASCO Reveals That Big Pharma Is Alive

by

This weekend, the annual American Society of Clinical Oncology (ASCO) kicked off in Chicago. The theme this year? Immunotherapy. The conference is traditionally littered with news from biotech companies revealing results from clinical studies, but this year’s event also included some news from big phama companies that haven’t been bursting with pipeline breakthroughs in years. Let’s take a look at some of the news out of the event. Firms Highlighted: Bristol-Myers Squibb, Merck, GlaxoSmithKline, Amgen, Galena Biopharma, BioMarin, Celgene. Bristol-Myers Squibb Source: BMY ASOC 2013 Presentation Bristol-Myers Squibb (click ticker for report: ) isn’t exactly what we’d call an under-appreciated company. Over the past year, shares are up 43%. However, this year’s ASCO only further ignited the fire. The company … Read more

Bristol-Myers Squibb Beats Estimates

by

Despite facing a steep patent cliff, pharmaceutical firm Bristol-Myers Squibb (click ticker for report: ) posted decent fourth-quarter results Thursday morning. Revenue declined 23% year-over-year to $4.2 billion, slightly better than the consensus prediction. Operating earnings per share declined 11% year-over-year to $0.47, which was also better than consensus estimates. 2012 was expected to be a tough year for the company, as it had US patents expire on Plavix and Avapro/Avalide, and total sales fell 23% for the quarter. However, strong international growth of 6% allowed the company to achieve 12% revenue expansion, excluding the aforementioned drugs. Costs were also reduced substantially, as the firm cut advertising and product-promotion spending 26% year-over-year to $212 million and slashed SG&A spending 6% … Read more

The Valuentum Dividend100 Publication; A Must-Have For Any Income Investor

by

Dividend investors literally have thousands of income stocks to choose from. So what are they to do, and where can they go for the most trusted forward-looking opinions on dividend growth and safety? That’s the question we seek to answer with our ValuentumDividend100 publication. In this document, we showcase the top 100 high-quality, dividend growth gems within our coverage universe. Whether you’re looking to build a portfolio consisting of high-yielding, dividend-growers or simply seeking to augment it with a few income gems, the Valuentum Dividend100 is an essential resource for any income investor. We outline some of the key components of our Dividend100 publication below, and explain how you can get the most from each of one Sign Up for … Read more

Inside AbbVie: A Look at a New Pharmaceutical Giant

by

On January 1, medical giant Abbott (click ticker for report: ) will start trading as two firms, Abbott and AbbVie. The companies will form two distinct, publicly-traded businesses, allowing the market to value each company separately and uniquely. Pharmaceuticals will be housed in AbbVie, while medical diagnostics, baby food, and generic drugs will remain a part of Abbott. Let’s first dig into AbbVie. We’ll have a follow up article on the new Abbott in coming days. AbbVie Led by Humira Headlining the new pharmaceuticals business is the blockbuster drug Humira, which had over $7.9 billion in sales in 2011 alone. Though originally approved for rheumatoid arthritis in 2003, the drug has been approved to treat Crohn’s disease, plaque psoriasis, ulcerative … Read more

AstraZeneca Is Not Immune to Patent Cliff

by

On Thursday, AstraZeneca (click ticker for report: ) posted difficult third-quarter results as the loss of exclusivity on several brands (namely Seroquel IR) and a couple divestitures drove revenue 15% lower. Core earnings per share declined 8%, while reported earnings per share dropped 50%. Still, management reiterated its full-year 2012 financial targets for earnings per share between $6.00 and $6.30 per share, and we don’t expect to make a material change to our fair value estimate at this time. The headline numbers were poor. US revenues dropped 19% in the third quarter, as a result of the loss of exclusivity of Seroquel IR, while revenue in the rest of the world (ROW) fell 12% during the period. The company noted … Read more

Bristol-Myers Squibb Cancer Drug Shows Promise

by

Drug maker Bristol-Myers Squibb (BMY) reported some promising results in a Phase-I trial for a cancer drug that helps the body fight cancer cells by harnessing the patient’s immune system.   Link to the trial study results: http://seekingalpha.com/news-article/3046321-investigational-anti-pd-1-immunotherapy-bms-936558-showed-clinical-activity-in-phase-1-trial-of-patients-with-previously-treated-non-small-cell-lung-cancer-metastatic-melanoma-and-renal-cell-cancer   Though the sample size was relatively small, the firm’s study showed that the immune system was more responsive while under drug therapy. Nevertheless, this is the first stage of a very long process to approval, and we aren’t too excited about shares at current levels. We prefer Pfizer (PFE) or Teva Pharmaceuticals (TEVA) at current levels on the basis of our Valuentum Buying Index.   Please click the following link to view our reports on the pharmaceutical industry:   /20110914_1

Looking for a Pullback to Pick Up Johnson & Johnson’s Shares

by

This article appeared on Seeking Alpha. Please view disclosures: https://seekingalpha.com/article/278789-looking-for-a-pullback-to-pick-up-johnson-and-johnsons-shares As long-time followers of Johnson & Johnson (click ticker for report: ) know, the firm is a steady, established company that has pursued somewhat of a defensive strategy in light of the global economic situation, which continues to muddle along in the US. J&J has pulled back on capital expenditures and R&D, while cutting overhead expenses, amounting to material operating savings. Operating margins have improved from about 26.6% in 2008 to over 27.5% in 2010, and we think there is further room for expansion in coming years. We believe these operating improvements to be a low risk measure to improve the bottom line, and with expansion into international markets, the firm should … Read more